ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0424

Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis

Kristina Wells1, Marcela Ferrada2, Emily Rose2, Keith Sikora3, Wendy Goodspeed2, Kaitlin Quinn4 and Peter C. Grayson5, 1Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, 2Systemic Autoimmunity Branch, Vasculitis Translational Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 3National Institutes of Health Clinical Center, Bethesda, MD, 4Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Washington, DC, 5Systemic Autoimmunity Branch, National Institutes of Health, NIAMS, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Biomarkers, cartilage, Collagen, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Relapsing polychondritis (RP) is a highly heterogenous systemic inflammatory disorder that affects many organ systems, in particular, cartilaginous structures. Clinical presentations in RP are variable, making recognition and diagnosis of the disease challenging. Testing for anti-collagen II (CII) antibodies is sometimes used to confirm the diagnosis of RP; however, the data remains inconclusive as to what percentage of RP patients have anti-CII antibodies in their serum. Our objectives were to evaluate the utility of anti-CII antibody as a diagnostic tool and as a possible objective measure of disease activity in a large cohort of patients with RP.

Methods: Patients 18 years and older were recruited into a prospective observational cohort of RP. All patients met McAdams or Damiani’s diagnostic criteria for RP.  Anti-Cll antibodies were assayed via a clinically certified ELISA test (Mayo Clinic, Rochester, MN) in all patients evaluated from July 2019 to March 2020. Clinical features were compared between patients with RP stratified by presence of anti-CII antibody results using Fisher’s exact test or Wilcoxon rank sum test as appropriate. Linear regression was used to determine if antibody titer correlated to Physician Global Assessment (PGA) score of disease activity. Clinical ELISA test results were compared to results using a different ELISA test platform (cat. no. 2065, Chondrex Inc., Redmond, WA, USA).

Results: Forty-six patients were tested, and six patients (13%) had elevated levels of anti-CII antibodies. Of four patients (8%) who had repeat testing, anti-CII antibodies were persistently negative in 3 patients and discordant positive/negative in 1 patient.  Patients with elevated anti-CII antibodies compared to those without elevated antibodies were female (100 vs 63%, p = 0.02) with a significantly higher prevalence of oral ulcers (50 vs 15%, p = 0.04), genital ulcers (33 vs 5%, p = 0.02), costochondritis (66 vs 25%, p = 0.048), and Sicca symptoms (83 vs 33%, p = 0.03) and with a significantly lower prevalence of eye inflammation (0 vs 40%, p = 0.018), as well as lower absolute monocyte (median 0.33 vs 0.51 K/uL, p = 0.02) and white blood cell counts (median 4.54 vs 6.95 K/ul, p = 0.049).  There was no correlation between antibody titer and PGA (r= 0.18; p = 0.33). A total of 24 patients were tested on both ELISA platforms. Twenty-three patients tested negative on both platforms, but 1 patient that tested positive by the Mayo Clinic ELISA tested negative by the Chondrex ELISA. Thus, there was little concordance between platforms.

Conclusion: Anti-CII antibodies likely have a limited role as a diagnostic test or biomarker of disease activity in RP.  Few patients with RP have detectable anti-CII antibodies, and detection of these antibodies is dependent on testing platform. Presence of anti-CII antibodies may be associated with specific clinical symptoms and may be enriched in a subset of patients with RP who have mucocutaneous disease.  This subset is commonly referred to as MAGIC syndrome (mouth and genital ulcers with inflamed cartilage).  Whether anti-CII antibodies provide pathogenic insight for a smaller subset of patients with RP remains to be determined.


Disclosure: K. Wells, None; M. Ferrada, None; E. Rose, None; K. Sikora, None; W. Goodspeed, None; K. Quinn, None; P. Grayson, None.

To cite this abstract in AMA style:

Wells K, Ferrada M, Rose E, Sikora K, Goodspeed W, Quinn K, Grayson P. Anti-Collagen II Antibodies in Patients with Relapsing Polychondritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-collagen-ii-antibodies-in-patients-with-relapsing-polychondritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-collagen-ii-antibodies-in-patients-with-relapsing-polychondritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology